Covered recipient · General Payments record
AKASH PATEL
General Payments · PY2022–2024
$2,299.29
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $594.08 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABIOMED | $279.93 | 3 |
| ABBVIE INC. | $222.46 | 11 |
| Janssen Pharmaceuticals, Inc | $65.47 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $26.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.68 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190101 | CMS |
| ABBVIE INC. | $19.36 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190103 | CMS |
| ABBVIE INC. | $14.55 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190105 | CMS |
| ABBVIE INC. | $15.33 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190107 | CMS |
| ABBVIE INC. | $34.11 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190109 | CMS |
| ABBVIE INC. | $24.53 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190111 | CMS |
| ABBVIE INC. | $30.96 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190113 | CMS |
| ABBVIE INC. | $19.81 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190115 | CMS |
| ABBVIE INC. | $9.53 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190117 | CMS |
| ABBVIE INC. | $28.79 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190119 | CMS |
| ABBVIE INC. | $10.81 | 11/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105190121 | CMS |
| ABIOMED | $65.65 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142282435 | CMS |
| ABIOMED | $97.68 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142282419 | CMS |
| ABIOMED | $116.60 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142282475 | CMS |
| Boston Scientific Corporation | $26.22 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092721026 | CMS |
| Janssen Pharmaceuticals, Inc | $27.33 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077933539 | CMS |
| Janssen Pharmaceuticals, Inc | $14.16 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077933537 | CMS |
| Janssen Pharmaceuticals, Inc | $23.98 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077933403 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.